Preliminary results from two early-phase clinical trials suggest that the investigational drug ibrutinib may benefit some patients with an aggressive type of non-Hodgkin lymphoma (NHL). In the trials, some patients with diffuse large B-cell lymphoma (DLBCL) who did not respond to standard therapies, or who had stopped responding to these treatments, experienced complete or substantial tumor shrinkage after treatment with ibrutinib. The treatment was well tolerated, with only minor side effects.
Dr. Louis Staudt of NCI’s Center for Cancer Research (CCR), who co-led both trials, presented the findings April 1 at the 2012 American Association for Cancer Research annual meeting in Chicago. Read more > >
- Senate Appropriations Hearing Highlights NCI’s Provocative Questions Project
- FDA Takes Action under the Tobacco Control Act of 2009
- Cyber-Seminar will Explore Measuring the Health of a Community
- Dr. John Potter to Deliver First Schatzkin Lecture in Nutritional Epidemiology